Simona Colla
Overview
Explore the profile of Simona Colla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
4841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rodriguez-Sevilla J, Colla S
Blood
. 2024 Mar;
143(11):941-943.
PMID: 38483410
No abstract available.
12.
Patel B, Zhou Y, Babcock R, Ma F, Zal M, Kumar D, et al.
Leukemia
. 2024 Mar;
38(5):1143-1155.
PMID: 38467768
Hematopoietic stem and progenitor cells (HSPCs) maintain blood-forming and immune activity, yet intrinsic regulators of HSPCs remain elusive. STAT3 function in HSPCs has been difficult to dissect as Stat3-deficiency in...
13.
Thongon N, Ma F, Baran N, Lockyer P, Liu J, Jackson C, et al.
Nat Commun
. 2024 Feb;
15(1):1203.
PMID: 38331987
DNA damage resistance is a major barrier to effective DNA-damaging therapy in multiple myeloma (MM). To discover mechanisms through which MM cells overcome DNA damage, we investigate how MM cells...
14.
Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, et al.
Lancet Haematol
. 2024 Feb;
11(3):e186-e195.
PMID: 38316133
Background: Hypomethylating agents are approved in higher-riskmyelodysplastic syndromes. The combination of a hypomethylating agent with venetoclax is standard of care in acute myeloid leukaemia. We investigated the safety and activity...
15.
Rodriguez-Sevilla J, Colla S
Blood
. 2024 Jan;
143(14):1329-1343.
PMID: 38237139
Escape from immune surveillance is a hallmark of cancer. Immune deregulation caused by intrinsic and extrinsic cellular factors, such as altered T-cell functions, leads to immune exhaustion, loss of immune...
16.
Adema V, Ganan-Gomez I, Ma F, Rodriguez-Sevilla J, Chien K, Yang H, et al.
bioRxiv
. 2023 Oct;
PMID: 37808770
Myelodysplastic syndromes (MDS) are a group of incurable hematopoietic stem cell (HSC) neoplasms characterized by peripheral blood cytopenias and a high risk of progression to acute myeloid leukemia. MDS represent...
17.
Jia Y, Han L, Ramage C, Wang Z, Weng C, Yang L, et al.
Haematologica
. 2023 Apr;
108(10):2626-2638.
PMID: 37078252
BCL-XL and BCL-2 are key anti-apoptotic proteins and validated cancer targets. 753B is a novel BCL-XL/BCL-2 proteolysis targeting chimera (PROTAC) that targets both BCL-XL and BCL-2 to the von Hippel-Lindau...
18.
Montalban-Bravo G, Ma F, Thongon N, Yang H, Gomez I, Rodriguez-Sevilla J, et al.
bioRxiv
. 2023 Apr;
PMID: 37066354
pathway mutations, which are present in 30% of patients with chronic myelomonocytic leukemia (CMML) at diagnosis, confer a high risk of resistance to and progression after hypomethylating agent (HMA) therapy,...
19.
Thongon N, Ma F, Lockyer P, Baran N, Liu J, Jackson C, et al.
bioRxiv
. 2023 Mar;
PMID: 36865225
Statement Of Significance: Metabolic reprogramming is a mechanism through which cancer cells maintain survival and become resistant to DNA-damaging therapy. Here, we show that targeting DNA2 is synthetically lethal in...
20.
STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity
Patel B, Zhou Y, Babcock R, Ma F, Zal M, Kumar D, et al.
bioRxiv
. 2023 Feb;
PMID: 36798265
STAT3 function in hematopoietic stem and progenitor cells (HSPCs) has been difficult to discern as deficiency in the hematopoietic system induces systemic inflammation, which can impact HSPC activity. To address...